Human-sourced strains
Probiotics are not created equally and its what's inside that really counts. Human Lactic Commensal (HLC) probiotics contain proprietary human-sourced microflora bacterial strains that possess a naturally strong physiological functionality.

Naturally strong adherence
A common probiotic misconception is that larger CFU (Colony Forming Unit) counts define probiotic effectiveness. While CFU counts do play a part in therapy, a probiotic supplement can only be effective if the strains utilized are able to latch onto the intestinal tract. HLC strains have a naturally strong adherence to epithelial cells thus ensuring high ratios of intestinal tract carriage.

Natural pH and bile acid resistance
Gastric pH may vary during the course of a day, from 1.8-4.2. HLC probiotics have high survival rates through the stomach under all conditions and maximize exposure in the GI tract, thus eliminating the need for enteric coatings that control digestive absorption.

Leveraging the natural gut flora hierarchy
HLC products utilize lactic acid-producing bacteria because of their anaerobic nature (not requiring oxygen to grow) and natural predominance in specific gastrointestinal tract locations. These lactic acid-producing bacteria strains include the genus Lactobacillus and Bifidobacterium. Leveraging the existing ecological hierarchy already present in the intestinal tract, daily probiotic supplementation therapies help to restore the dominance of Lactobacilli in the small intestine and Bifidobacteria in the large intestine, ensuring a critical balance while replenishing and maintaining beneficial strains.

Proprietary-sourcing, proprietary strains
The Darwinian approach of natural selection—"strongest" and "smartest" adapt to survive—has been incorporated into HLC probiotics. As human-sourced probiotics are non-pathogenic, this proprietary process identifies top-conditioned hosts and targets only the strongest strains.

Clinically proven
Randomized, double-blind, placebo-controlled human trials demonstrate HLC safety and efficacy.

• Safe to use in pregnancy.
• Reduce IBS symptoms within 2-10 week period.
• Maintain gut flora balance during post-antibiotic therapy.
• Reduced the incidence and total numbers of antibiotic resistant strains after antibiotic therapy.
• Reduced the incidence of C. difficile associated diarrhea from 67% to 18% in a pilot study.

Comprehensive range—Age-specific and conditionspecific support
Pharmax HLC probiotic therapies are available for various ages, conditions, and physiological requirements including pre- and post-pregnancy, infants (1 year +), children, adolescents, adults, and seniors. An array of potencies from 2.5 billion to 150 billion CFU (Colony Forming Units) per dose are available in a variety of formats (powders, chewable tablets, capsules, ovules, and sachets) to allow for flexibility in administration and patient compliance. Some of these therapies also include new innovative manufacturing processes: the addition of multi-nutrients to high-potency probiotics without compromising probiotic stability and overall product shelf life; as well as both refrigerated and ambient temperature (59-86º F) storage formulas.

Probiotic expertise from Dr. Nigel Plummer
Much of the research and development of Pharmax HLC probiotics is credited to Dr. Nigel Plummer. Dr. Plummer has his doctorate in microbial physiology and has worked in antibiotic research and development. His research on the use of normal flora in the prevention and treatment of genito-urinary candidiasis has won him numerous awards. Dr. Plummer lectures extensively throughout North America and Europe, sharing his expertise on the topic of healthy intestinal flora.